Lonigutamab Ugodotin is a monoclonal antibody commercialized by Acelyrin, with a leading Phase II program in Graves’ Ophthalmopathy. According to Globaldata, it is involved in 3 clinical trials, of which 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Lonigutamab Ugodotin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Lonigutamab Ugodotin is expected to reach an annual total of $311 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Lonigutamab Ugodotin Overview

VB-421 is under development for the treatment of thyroid eye disease (TED, Graves ophthalmopathy) and other autoimmune, inflammatory and fibrotic disorders. The drug candidate is a humanized immunoglobulin G1 (IgG1) monoclonal antibody, administered through subcutaneous route. It acts by targeting insulin like growth factor 1 receptor (IGF-1R).

Acelyrin Overview

Acelyrin is a biopharma company that identifies, acquires, and accelerates the development and commercialization of transformative medicines. It focuses on creating value for patients and shareholders. The company’s products include izokibep, Lonigutamab (anti-IGF-1R), XLRN-517 (anti-C-KIT). Acelyrin pipeline treats hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, uveitis, thyroid eye disease, and chronic urticaria.
The operating loss of the company was US$422.1 million in FY2023, compared to an operating loss of US$69.2 million in FY2022. The net loss of the company was US$381.6 million in FY2023, compared to a net loss of US$64.8 million in FY2022.

For a complete picture of Lonigutamab Ugodotin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.